Michael S. Hearne - 18 May 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Financial Officer
Issuer ticker: AUPH
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2026, 17:04:48 UTC
Prior SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Hearne

Key filing fact

Michael S. Hearne filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 20 May 2026.

Key facts

This page summarizes Michael S. Hearne's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 May 2026, 17:04.

Change

Previous filing in this sequence was filed on 02 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001759910 Primary reporting owner

Hearne Michael S

Relationship: Chief Financial Officer
Address: #140, 14315 - 118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature: /s/ Michael Hearne
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value
Shares: +116,144
Change %
Price: $0.000000^*
Shares after: 116,144
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUPH transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +70,230
Change %
Price: $0.000000^*
Shares after: 70,230
Date: 18 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,230
Exercise price: $15.28
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 46,820 PSUs vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. 69,324 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.

Footnote F2

33% vest on the 1-year anniversary of the grant date, and the remaining 67% vest equally in monthly installments over the following 2 years.